ABSTRACT
El edema idiopático es un diagnóstico de exclusión, caracterizado por la acumulación de líquido en tejido intersticial en mujeres premenopáusicas en ausencia de patología cardiaca, renal o hepática. Típicamente los laboratorios y estudios complementarios son normales. El tratamiento es la Espironolactona debido al Hiperaldosteronismo secundario concomitante. De no ser efectivo, puede ser añadido o cambiado a un diurético tiazídico a la menor dosis efectiva. Es frecuente la resistencia a este grupo farmacológico.
Idiopathic edema is a diagnosis of exclusion, characterized by the accumulation of fluid in interstitial tissue in premenopausal women in the absence of cardiac, renal or hepatic pathology. Typically laboratories and complementary studies are normal. Treatment is Spironolactone due to concomitant secondary hyperaldosteronism. If not effective, it can be added or changed to a thiazide diuretic at the lowest effective dose. Resistance to this pharmacological group is frequent.
Subject(s)
Humans , Female , Diagnosis , Hypereosinophilic Syndrome/bloodABSTRACT
We report a case of chronic eosinophilic leukemia in a 9 year old girl who presented with anemia, thrombocytopenia, leucocytosis (mostly dysplastic eosinophils), lymphadenopathy and hepatosplenomegaly. There was no increase in blasts but myelofibrosis was seen in the bone marrow. A previously unreported translocation 46,XX,t(1;4)(q24;q35), was found on cytogenetic analysis and involvement of the myocardium was also present. Shortly after commencing steroids, the family abandoned therapy.
Subject(s)
Cardiomyopathies/blood , Cardiomyopathies/diagnosis , Cardiomyopathies/drug therapy , Cardiomyopathies/genetics , Child , Chronic Disease , Echocardiography , Eosinophils , Female , Glucocorticoids/therapeutic use , Humans , Hypereosinophilic Syndrome/blood , Hypereosinophilic Syndrome/diagnosis , Hypereosinophilic Syndrome/drug therapy , Hypereosinophilic Syndrome/genetics , Translocation, GeneticABSTRACT
We report here a case with hypereosinophilia and peripheral artery occlusion. A 32-yr-old Korean woman presented to us with lower extremity swelling and pain. Angiography revealed that multiple lower extremity arteries were occlusive. The biopsy specimen showed perivascular and periadnexal dense eosinophilic infiltration in dermis and subcutaneous adipose tissue. Laboratory investigations revealed a persistent hypereosinophilia. She was prescribed prednisolone 60 mg daily. Her skin lesion and pain were improved and the eosinophil count was dramatically decreased. After discharge, eosinophil count gradually increased again. Cyanosis and pain of her fingers recurred. She had been treated with cyclophosphamide pulse therapy. Her eosinophilia was decreased, but the cyanosis and tingling sense were progressive. The extremity arterial stenoses were slightly progressed. Skin biopsy showed perivascular eosinophilic infiltration in the dermis and CD40 ligand (CD40L) positive eosinophilic infiltration. The serum TNF-alpha was markedly increased. These results suggest that CD40L (a member of TNF-alpha superfamily) could play a role in the inflammatory processes when eosinophil infiltration and activation are observed. We prescribed prednisolone, cyclophosphamide, clopidogrel, cilostazol, beraprost and nifedipine, and she was discharged.
Subject(s)
Adult , Female , Humans , Arterial Occlusive Diseases/diagnosis , CD40 Ligand/analysis , Cyanosis/etiology , Diagnosis, Differential , Eosinophilia/diagnosis , Gangrene/etiology , Hypereosinophilic Syndrome/blood , Immunohistochemistry , Peripheral Vascular Diseases/diagnosis , Skin/chemistry , Tumor Necrosis Factor-alpha/metabolism , Vasculitis/diagnosisABSTRACT
The hypereosinophilic syndrome (HES) is a heterogeneous disease characterized by sustained eosinophilia for a period of at least six months with evidence of organ involvement. Its manifestations range from a benign disorder not requiring any therapy to an aggressive, malignant variety refractory to common treatments. Diverse therapies have been used, including steroids, hydroxyurea, and chemotherapy, with variable responses. Recently alpha-interferon therapy has been shown effective in this disorder. Of the various prognostic factors, elevated serum immunoglobulin E (IgE) levels is considered among the most favorable, with most patients presenting with a [quot ]benign[quot ] disorder, not requiring therapy. We describe a patient presenting with an aggressive variant of HES despite having elevated IgE levels. The patient had a dramatic and lasting response to alpha-interferon